Valley National Advisers Inc. Has $130,000 Holdings in ARK Genomic Revolution ETF $ARKG

Valley National Advisers Inc. decreased its position in ARK Genomic Revolution ETF (BATS:ARKG) by 15.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,371 shares of the company’s stock after selling 1,001 shares during the period. Valley National Advisers Inc.’s holdings in ARK Genomic Revolution ETF were worth $130,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. NBC Securities Inc. raised its stake in ARK Genomic Revolution ETF by 137,400.0% during the 1st quarter. NBC Securities Inc. now owns 1,375 shares of the company’s stock valued at $28,000 after purchasing an additional 1,374 shares during the period. SG Americas Securities LLC raised its position in ARK Genomic Revolution ETF by 360.9% during the first quarter. SG Americas Securities LLC now owns 143,288 shares of the company’s stock valued at $2,975,000 after buying an additional 112,201 shares during the period. Sowell Financial Services LLC purchased a new stake in ARK Genomic Revolution ETF in the 1st quarter worth about $344,000. Cambridge Investment Research Advisors Inc. lifted its stake in ARK Genomic Revolution ETF by 0.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 94,117 shares of the company’s stock worth $1,954,000 after acquiring an additional 839 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in ARK Genomic Revolution ETF during the 1st quarter worth about $387,000.

ARK Genomic Revolution ETF Stock Up 28.7%

BATS:ARKG opened at $30.40 on Tuesday. ARK Genomic Revolution ETF has a fifty-two week low of $17.51 and a fifty-two week high of $31.16. The stock’s 50-day moving average is $25.61 and its two-hundred day moving average is $23.66.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.